Physician profile
Michael S Baugh
NPI 1295840577
$23,259.01
in general payments reported to CMS, 2019-2025
70 companies · $3,440 in 2025
The $3,440 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,991 · 2020: $2,285 · 2021: $3,253 · 2022: $3,513 · 2023: $3,685 · 2024: $4,091 · 2025: $3,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,216.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,386.37 | 2019-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $1,800.58 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Biogen, INC. | $1,141.10 | 2019-2025 | Vumerity, Tysabri |
| Amgen INC. | $953.59 | 2019-2025 | Uplizna, Aimovig |
| Pfizer INC. | $925.91 | 2021-2025 | |
| Neurelis, INC. | $874.46 | 2020-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $850.72 | 2019-2025 | |
| Mdd US Operations, LLC | $850.45 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Neurocrine Biosciences, INC. | $821.91 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $705.06 | 2019-2025 | |
| Allergan, INC. | $669.54 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $634.44 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $578.01 | 2021-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $577.52 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $544.03 | 2019-2025 | Nuplazid |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.